Paridopa 50/12.5/200mg 30s
Levodopa, carbidopa, and entacapone combination for Parkinson's disease.
Paridopa 50/12.5/200mg combines levodopa, carbidopa, and entacapone in a single tablet for Parkinson's disease. Levodopa is converted to dopamine in the brain; carbidopa reduces peripheral conversion; entacapone prolongs the effect of levodopa by inhibiting COMT. Used when standard levodopa/carbidopa response wears off between doses.
Purpose
Treatment of Parkinson's disease in patients experiencing end-of-dose motor fluctuations on levodopa/carbidopa.
Ingredients
Levodopa 50mg, carbidopa 12.5mg, entacapone 200mg per tablet.
Warnings
Contraindicated in narrow-angle glaucoma, phaeochromocytoma, and with non-selective MAO inhibitors. Do not stop abruptly. Caution in cardiovascular disease. May cause drowsiness and orthostatic hypotension.
Side Effects
Dyskinesia, nausea, diarrhoea, urine discolouration (harmless), dizziness, orthostatic hypotension. Rare: neuroleptic malignant syndrome on abrupt withdrawal. Report severe diarrhoea or fainting.
Storage Instructions
Store below 25°C in a dry place. Keep in original pack; protect from light and moisture.
| Brand | Pharmevo |
| Status | Active |
Related Products
Nermiro 15mg tab 14s
Nermiro contains Mirogabalin Besilate, a prescription medicine that reduces nerve pain signals.
